title: A Phase II Study of Paclitaxel and Cisplatin Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
abstract: OBJECTIVE
  Paclitaxel and cisplatin, active drugs in the treatment of non-small-cell lung cancer (NSCLC), have been found to be synergistic and less myelotoxic in combination when the paclitaxel is given 24 hr prior to the cisplatin. Their antitumor activity and toxicity in patients with advanced NSCLC has been evaluated herein.
  
  
  METHODS
  Seventy-four chemonaive patients, with advanced NSCLC, were enrolled. Paclitaxel, 175 mg/m2, was administered on day 1, followed 24 hr later by cisplatin, 75 mg/m2, on day 2.
  
  
  RESULTS
  The overall response rate, median time to progression and median survival time were 51%, 7.1 months (95% confidence interval (CI), 5.5~8.7 months) and 13.7 months (95% CI, 11.3~16.1 months), respectively. There were significant differences in the overall survival rates in relation to stage and the ECOG performance status(PS). The toxicity was mainly nonhematological. Grade > or =3 neuropathy occurred in 2 (3%) patients, myalgia in 3 (4%), and bone pain in 3 (4%). The hematological toxicity was mild, and no grade 3 or 4 neutropenia was observed.
  
  
  CONCLUSIONS
  The combination of paclitaxel and cisplatin is an effective and tolerable treatment regimen for advanced NSCLC during first line chemotherapy. The main toxicity was nonhematological, such as peripheral neuropathy, myalgia and bone pain, whereas the hematological toxicity itself was mild.
authors.forename: Jung Ae
authors.initials: JA
authors.lastname: Lee
authors.forename: Keun Seok
authors.initials: KS
authors.lastname: Lee
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Ahn
authors.forename: Jae Ho
authors.initials: JH
authors.lastname: Byun
authors.forename: Hun Ho
authors.initials: HH
authors.lastname: Song
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Zang
authors.forename: Young Iee
authors.initials: YI
authors.lastname: Park
authors.forename: Young Suk
authors.initials: YS
authors.lastname: Park
authors.forename: Eun Kyung
authors.initials: EK
authors.lastname: Mo
authors.forename: Dong Kyu
authors.initials: DK
authors.lastname: Kim
authors.forename: Myung Goo
authors.initials: MG
authors.lastname: Lee
authors.forename: In Gyu
authors.initials: IG
authors.lastname: Hyun
authors.forename: Ki Suck
authors.initials: KS
authors.lastname: Jung
authors.forename: Soo Mee
authors.initials: SM
authors.lastname: Bang
authors.forename: Gye Young
authors.initials: GY
authors.lastname: Park
authors.forename: Jeong Woong
authors.initials: JW
authors.lastname: Park
authors.forename: Eun Kyung
authors.initials: EK
authors.lastname: Cho
authors.forename: Seong Hwan
authors.initials: SH
authors.lastname: Jeong
authors.forename: Dong Bok
authors.initials: DB
authors.lastname: Shin
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
keywords: Cisplatin; Non-small-cell lung cancer; Paclitaxel